Genetic Screening of Newborns
An Ethical Inquiry
Seiten
2010
Nova Science Publishers Inc (Verlag)
978-1-60876-068-8 (ISBN)
Nova Science Publishers Inc (Verlag)
978-1-60876-068-8 (ISBN)
The majority of babies born in the US each year undergo screening soon after birth to identify genetic defects that could cause serious illness if left undetected and untreated. This title looks at genetic screening of new-borns and the ethical principles that guide this practice.
This book looks at genetic screening of new-borns and the ethical principles that guide this practice. The majority of babies born in the U.S. each year undergo screening soon after birth to identify genetic defects that could cause serious illness if left undetected and untreated. The goal is to detect diseases as early as possible so that timely, effective treatment can be initiated even before the onset of symptoms. In most states, new-born screening is now mandated by law. Of the approximately four million babies screened each year, about 5,000 are identified as having serious heritable disorders, most of which are, in varying degrees, amenable to treatment. For more than 40 years, the moral focus of new-born screening has been what is good for the infant. However, as more and more disorders have been added to state new-born screening programs, the traditional ethical principles of screening have been called into question. This aim of this study is to foster public awareness of the practice of new-born screening, the ethical principles that have guided it until now, and the ethical problems posed by its current and future expansion. This book consists of public documents which have been located, gathered, combined, reformatted, and enhanced with a subject index, selectively edited and bound to provide easy access.
This book looks at genetic screening of new-borns and the ethical principles that guide this practice. The majority of babies born in the U.S. each year undergo screening soon after birth to identify genetic defects that could cause serious illness if left undetected and untreated. The goal is to detect diseases as early as possible so that timely, effective treatment can be initiated even before the onset of symptoms. In most states, new-born screening is now mandated by law. Of the approximately four million babies screened each year, about 5,000 are identified as having serious heritable disorders, most of which are, in varying degrees, amenable to treatment. For more than 40 years, the moral focus of new-born screening has been what is good for the infant. However, as more and more disorders have been added to state new-born screening programs, the traditional ethical principles of screening have been called into question. This aim of this study is to foster public awareness of the practice of new-born screening, the ethical principles that have guided it until now, and the ethical problems posed by its current and future expansion. This book consists of public documents which have been located, gathered, combined, reformatted, and enhanced with a subject index, selectively edited and bound to provide easy access.
Preface; The Changing Moral Focus of New-born Screening: An Ethical Analysis by the President's Council on Bioethics; Genetic Exceptionalism: Genetic Information & Public Policy; Genetic Testing: Scientific Background for Policymakers; Index.
Erscheint lt. Verlag | 1.7.2010 |
---|---|
Verlagsort | New York |
Sprache | englisch |
Maße | 230 x 155 mm |
Gewicht | 370 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Medizinethik |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pädiatrie | |
Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
Studium ► Querschnittsbereiche ► Geschichte / Ethik der Medizin | |
ISBN-10 | 1-60876-068-5 / 1608760685 |
ISBN-13 | 978-1-60876-068-8 / 9781608760688 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Eine sehr persönliche Geschichte | Der New York Times-Bestseller
Buch | Softcover (2023)
Ullstein Taschenbuch Verlag
21,99 €
Die revolutionäre Medizin von morgen (Lifespan)
Buch | Softcover (2020)
DuMont Buchverlag
16,00 €